APA (7th ed.) Citation

A, B., A, K., T, S., J, M., M, P., A, K., . . . P, S. (2021). Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn-Schmiedeberg's archives of pharmacology, 394(12), 2363. https://doi.org/10.1007/s00210-021-02149-4

Chicago Style (17th ed.) Citation

A, Bénardeau, et al. "Runcaciguat, a Novel Soluble Guanylate Cyclase Activator, Shows Renoprotection in Hypertensive, Diabetic, and Metabolic Preclinical Models of Chronic Kidney Disease." Naunyn-Schmiedeberg's Archives of Pharmacology 394, no. 12 (2021): 2363. https://doi.org/10.1007/s00210-021-02149-4.

MLA (9th ed.) Citation

A, Bénardeau, et al. "Runcaciguat, a Novel Soluble Guanylate Cyclase Activator, Shows Renoprotection in Hypertensive, Diabetic, and Metabolic Preclinical Models of Chronic Kidney Disease." Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 394, no. 12, 2021, p. 2363, https://doi.org/10.1007/s00210-021-02149-4.